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Background: Unfortunate complications in some patients 
who undergo minimally-invasive resections for colorectal 
cancer using a minilaparotomy are the development of post-
operative wound infection or tumor recurrence at in the 
minilaparotomy site. These complications are potentially 
avoidable. In an effort to prevent these problems, we de-
signed an easy-to-use device named the Lap-Protector TM. The 
purpose of this study was to evaluate the efficacy of the 
Lap-Protector TM in preventing bacterial infection and tumor 
recurrence at minilaparotomy incision sites. 
Patients and Methods: Ninety-eight colon cancer patients who 
underwent minimally-invasive resections using minilaparotomy 
(minilaparotomy or laparoscopic-assisted approach) with the 
assistance of the Lap-Protector TM between January 1999 and 
August 2000 were compared with 87 patients treated without 
this device between January 1997 and December 1998. 
Postoperative wound infection and tumor recurrence rates at 
the minilaparotomy site were retrospectively analyzed. 
Results: Patient characteristics (age, sex, body mass index, 
and frequency of diabetes mellitus), tumor location, opera-
tive procedures, and pathological parameters were similar 
between the two groups. Four patients (4.6%) in the con-
trol group developed postoperative wound infections versus 
none in the Lap-Protector TM group (P=0.047). With a me-
dian follow-up of 8.3 (range, 1.3 to 19.3) and 29.7 (range, 
8.4 to 54.4) months in the Lap-Protector TM group and con-
trol group, respectively, neither group has recorded a tumor 
recurrence at the minilaparotomy site. 
Conclusion: The Lap-Protector TM appears to prevent wound infec-
tion after minimally-invasive resections for colon cancer using 
a minilaparotomy. Longer follow-up to evaluate tumor recur-
rence rates at the minilaparotomy site is necessary. 
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Introduction
  The conventional surgery for colon cancers has been 
challenged by the minimally-invasive approaches of 
laparoscopy1-3' and minilaparotomy4,51, which, in compari-
son, seem to allow faster recovery and decreased post-
operative pain. At the completion of most laparoscopic 
colectomies, after laparoscopic mobilization of the bowel 
has been accomplished, a small 4 to 5-cm incision is made 
to allow extracorporeal anastomosis and removal of the 
specimen". The minilaparotomy approach to colorectal re-
section, as reported by Fleshman et a14. and Furstenberg 
et a15., involves utilizing the shortest possible incision 
through which all of components of the procedure can be 
performed. The use of a small incision, whether by 
minilaparotomy or by laparoscopy, resulted in an earlier 
return of bowel function and shorter hospital stay'. Thus, 
minilaparotomy is essential to performing either of these 
minimally-invasive approaches to colon tumor resections. 
 Unfortunate complications in some patients who un-
dergo minimally-invasive resections for colorectal can-
cer using a minilaparotomy are the development of 
postoperative wound infection by intestinal bacteria' .2,7) 
or tumor recurrence 2.1.1' at in the minilaparotomy site. 
These complications are potentially avoidable. In an ef-
fort to prevent these problems, we designed an easy-to-
use device named the Lap-ProtectorTM in collaboration 
with Hakko Co., Ltd. (Catalog No. 9908T; Nagano, 
Japan). The purpose of this study was to evaluate the ef-
ficacy of the Lap-ProtectorTM in preventing infection and 
tumor recurrence (short term) at the minilaparotomy 
site after laparoscopic-assisted and minilaparotomy ap-
proaches to colon cancers.
Patients and Methods
Patient population 
 One-hundred eighty-five patients who underwent 
laparoscopic-assisted or minilaparotomy approaches for 
complete resection of colon cancer between January 
1997 and August 2000 at Nagasaki University Hospital 
(Nagasaki, Japan) or Sasebo Municipal Hospital (Sasebo, 
Japan) were enrolled in this study. All patients included 
in this study underwent elective surgery in which the 
large bowel was opened. Exclusion criteria for both 
laparoscopic-assisted and minilaparotomy approaches 
included lack of informed patient consent, tumors 
larger than 6 cm, tumors infiltrating adjacent organs, 
intestinal obstruction or perforation, more than one 
carcinoma of the colon, and distant metastases. In ad-
dition, immunocompromised patients who had trans-
plantation, those with long-term steroid administration, 
or those undergoing intensive chemotherapy were ex-
cluded from this study. American Joint Committee on 
Cancer classification and stage grouping were used to 
classify the tumors"). 
 The Lap-Protector'"' was first used in January 1999, and 
thereafter, until August 2000, on 98 patients (Lap-
ProtectorTM group) undergoing minimally-invasive colonic 
resections for cancer. Prior to its use, from January 1997 
to December 1998, we performed minimally-invasive pro-
cedures without this device on 87 patients (controls) with 
similar indications. The Lap-ProtectorTM group consisted of 
11 patients who underwent laparoscopic-assisted ap-
proaches and 87 that underwent minilaparotomy ap-
proaches, whereas the control group consisted of 15 pa-
tients who underwent laparoscopic-assisted approaches 
and 72 patients with minilaparotomy approaches. 
 The two endpoints of postoperative infection and 
short-term tumor recurrence at the minilaparotomy 
wound were then evaluated and incidences retrospec-
tively compared between study groups.
Lap-ProtectorTM 
 The Lap-ProtectorTM consists of 2 flexible rings made 
of super-elastic alloys covered with polyurethane 
polyamide and a thin silicone rubber membrane that is 
attached to the outer edge of the two rings (Fig. 1-a). 
If the two rings are pulled apart, the device assumes 
a cylindrical shape with the outer diameter of each 
flexible ring 12 cm (Fig. 1-b). This device can be used 
for minilaparotomy wounds with lengths ranging from 
5 to 9 cm and is available commercially at Hakko Co., 
Ltd. (Catalog No. 9908T; Nagano, Japan), at a cost of 
Y 7,000 ($ 58, at an exchange rate of U.S. $ 1= k 120).
Fig. 1-a. Photograph of the Lap-ProtectorTM device.
Fig. 1-b. If the two rings are pulled apart, the device assumes 
a cylindrical shape.
Surgical techniques 
 In performing the laparoscopic-assisted approach, it 
was the surgeon's discretion whether or not to use a 
pneumoperitoneum. A small incision was made for 
extracorporeal bowel resection and anastomosis and re-
moval of the specimens after laparoscopic mobilization 
of the bowel was accomplished. The Lap-ProtectorTM 
was used only at the minilaparotomy incision, not at 
the trocar sites. 
 Our definition of the minilaparotomy approach for 
resection of colon cancer implies that complete resec-
tion using conventional surgical techniques and instru-
ments can be performed through a skin incision 
shorter than 7 cm. In performing the minilaparotomy 
approach, a small skin incision was made as the first 
operative step. The Lap-ProtectorTM was used at this 
minilaparotomy incision. 
 In preparation for inserting the Lap-ProtectorTM, the 
operator must slide the bottom ring halfway through 
the opening of the top ring at an angle of approxi-
mately 45° such that half of the bottom ring is above
the plane of the top ring. The bottom ring was ad-
vanced slowly into the peritoneal cavity through the 
incision such that it abutted the peritoneal surface of 
the abdominal wall (Fig. 2). With the opposite end of 
the bottom ring snapped into the frontal abdominal 
wall also, the device formed a sandwich with the ab-
dominal wall between the two rings, as the top ring 
remained on the skin surface of incision. The Lap-
Protector TI provided a round and relatively wide open-
ing in the abdomen due to the tension of the silicon 
rubber (Fig. 3).
Clinical management 
 Two to three liters of polyethylene glycol electrolyte so-
lution given one day pre-operatively served as bowel 
preparation. No oral bowel preparation with antimicrobials 
was performed preoperatively, nor was systemic prophy-
lactic administration conducted preoperatively or intraope-
ratively. All patients received a prophylactic, postoperative 
regimen of antibiotic (flomoxef sodium [FlumarinT"' 
Shionogi Co. Ltd., Tokyo, Japan] ), 2.0g/day intravenously 
for 5 consecutive days. No additional antibiotic was ad-
ministered for patients who developed postoperative 
wound infection; rather, skin incision and wound drainage 
were performed only.
Fig. 2. Figure depicting insertion of the Lap-ProtectorTM 
device into the peritoneal cavity through the small incision.
Wound infection 
 All data with respect to wound infection were col-
lected during the period of postoperative recovery, 
prior to discharge from the hospital. A minilaparotomy 
wound was regarded as infected if there was a puru-
lent discharge from the suture line or if there was a 
nonpurulent discharge that contained pathologic bacte-
ria. Aerobic and anaerobic cultures were performed in 
the microbiology department of our Hospital. Since the 
Lap-Protector" protects the minilaparotomy wound 
only, infectious complications from other sites in the 
operative fields (e.g. trocar sites or drainage tube 
sites) were excluded from this study.
Wound recurrence 
 Wound recurrence was defined as a tumor recur-
rence at the minilaparotomy wound in which the Lap-
Protector" was used. As the Lap-Protector" serves to 
protect only the minilaparotomy wound, tumor recur-
rences at trocar sites, anastomotic recurrences, or dis-
seminated peritoneal metastasis were excluded from 
this study.
Fig. 3. Figure depicting completion of attachment of the Lap-
Protector" device in the minilaparotomy wound.
 At the conclusion of the operation, the surgeon 
changed gloves prior to performing peritoneal lavage 
with saline. The bottom ring was then removed by 
squeezing the ring and pulling it out of the peritoneal 
cavity slowly. Similar suture materials for closure of 
the minilaparotomy were used in both groups. The 
minilaparotomy wounds were not drained. Any intra-
abdominal drainage tubes were brought out separately 
from the minilaparotomy wound.
Postoperative follow-up 
 No patients were lost to follow-up as of this writing 
(October, 2000). Median lengths of follow-up in the 
Lap-ProtectorTM group and Control group were 8.3 
months (range, 1.3 to 19.3 months) and 29.7 months 
(range, 8.4 to 54.4 months), respectively. The Lap-
ProtectorTM group included 22 patients whose follow-
up periods were longer than one year following sur-
gery.
Statistical analysis 
 Statistical analyses were performed using Statistical
software (Statsoft, Tulsa, OK). Continuous data were 
expressed as mean and standard deviations, and statis-
tical analyses were conducted using the unpaired t-
test. Categorical data were analyzed by x2 test or 
Fisher's exact test. Each test was two-tailed and a P 
value of less than 0.05 was considered significant.
Results
Comparison of Lap-Protector's' and Control groups 
 Patient characteristics such as age, sex, body mass 
index" (defined as weight in kilograms divided by 
height in meters'), frequency of diabetes mellitus, and 
tumor location (right colon vs. left colon) were similar 
between the two groups. 
 Mean values of minilaparotomy wound length in the 
Lap-Protector" and Control groups were 6.7 cm and 6.5 
cm, respectively; a non-significant difference. Operative 
procedures including operative time, operative blood 
loss, type of operation, and method of anastomosis 
were similar between the two groups. No patients re-
quired blood transfusions. 
 Pathological parameters (maximal tumor diameter, num-
ber of lymph nodes removed, histologic type and tumor 
stage) were also similar between the two groups, as was 
length of postoperative hospital stay (Table 1).
Wound infection 
 None of the 98 patients in the Lap-ProtectorTM group 
developed wound infection postoperatively, whereas 4 
of 87 patients (4.6%) in the Control group developed 
wound infection (P=0.047). Bacterial cultures mini-
laparotomy wounds suspected of infection revealed the 
following pathogens: Escherichia coli, Proteus spp., 
Pseudomonas aeruginosa, Bacteroides spp., and Entero-
coccus faecalis. All patients with suspected wound in-
fections were treated by incision and drainage and re-
ceived no additional antibiotic therapy. 
 There was no operative mortality in either group. 
Postoperative complications other than wound infection 
developed in 5 patients (5.7%; 3 intestinal obstructions, 
1 intra-abdominal abscess, and 1 anastomotic bleeding) 
within Control group and 5 patients (5.1%; 4 intestinal 
obstructions and 1 subcutaneous hematoma) within 
Lap-Protector" group. This difference was not statisti-
cally significant.
Wound recurrence during short-term follow-up 
 All patients in Lap-ProtectorTM group are alive
Table 1. Comparison of patient characteristics between Lap-
Protector" and control groups.
Variables Lap-Protector" Control group P value 
                            group (n=98) (n=87) 
Age (years) * 66.7 ± 12.0 65.3 ± 11.3 0.43 
Sex** 0.77 
 Female/Male 41 (41.8)/57 (58.2) 39 (44.8)/48 (55.2) 
BMI (kg/m2)- 22.5 ± 3.3 22.5 ±2.9 0.89 
Diabetes mellitus** 3(3.1) 4(4.6) 0.71 
Tumor location** 0.76 
 Right colon/Left colon 32 (32.7)/66 (67.4) 31 (35.6)/56 (64.4) 
Length of laparotomy wound (cm)* 6.7 ± 1.0 6.5 ± 1.3 0.25 
Operation time (min.)* 170.8 ± 54.1 180.9 ± 55.9 0.21 
Operative blood loss (ml)* 60.2 ± 118.2 77.3 ± 131.5 0.35 
Operation** 0.17 
 Ileocecal resection 15 (15.3) 11 (12.6) 
 Right hemicolectomy 11 (11.2) 6(6.9) 
 Transverse colectomy 5(5.1) 8(9.2) 
 Left partial colectomy 7(7.1) 5(5.7) 
 Sigmoid colectomy 56 (57.1) 45 (51.7) 
 Surgical polypectomy 4(4.1) 12(13.8) 
Anastomosis** 0.85 
 Hand-sewn/ Stapled 80 (81.6)/18 (18.4) 70 (80.5)/17 (19.5) 
Maximal tumor diameter (cm)* 3.0 ± 17.6 2.7 ± 12.1 0.23 
No. of lymph node removed* 10.6 ± 9.9 10.5 ± 9.2 0.94 
Histologic type*1 0.22 
 Well 64 (65.3) 51 (58.6) 
 Moderately 30 (30.6) 35 (40.2) 
 Poorly/ Mucinous 4(4.0) 1(l.2) 
Stage** 0.065 
 I 53 (54.1) 61(70.1) 
 II 28 (28.6) 14(16.1) 
 III 17 (17.4) 12 (13.8) 
Postoperative hospital stay (days) 14.3 ± 6.5 15.5 ± 5.5 0.18
* Values are expressed as mean ± standard deviation
, and statistical analyses are 
conducted by unpaired t-test.
** Values are expressed as number of patients (%)
, and statistical analyses are conducted 
by Fisher's exact test or x2 test.
¶ Well, Moderately, Poorly, and Mucinous denote well differentiated adenocarcinoma, 
moderately differentiated adenocarcinoma, poorly differentiated adenocarcinoma, and 
mucinous carcinoma.
without tumor recurrence, 22 of whom have follow-up 
exceeding 12 months. Six patients (6.9%) in the
Control group have developed tumor recurrence (me-
tastasis to liver, lung, and/or ovary), 3 of whom are 
alive and 3 of whom have died of colon cancer. 
 No patients developed tumor recurrence at the 
minilaparotomy wound in either group. Similarly, no 
patient who underwent the laparoscopic-assisted ap-
proach developed tumor recurrence at port sites.
Discussion
 The current study demonstrates that the Lap-
Protector" is useful in preventing infection of the 
minilaparotomy wound during minimally-invasive pro-
cedures (laparoscopic-assisted or minilaparotomy ap-
proaches) to colon cancers. 
 Assuming laparoscopy to be a less invasive ap-
proach, some investigators have anticipated reduced 
rates of wound complications such as infections and 
adhesions',","'. In fact, early reports suggested that 
laparoscopy in colorectal surgery might be associated 
with fewer postoperative infections, with rates of 3.6% 
and 1.2% for laparoscopic and 7.9% and 12.7% for 
open surgery reported in 2 series 12,11) However, recent 
studies continue to report wound infection rates after 
laparoscopic-assisted approaches to colorectal cancer 
resections ranging from 2.9% to 8.2%17). Wound infec-
tion after the minilaparotomy approach also developed 
at a rate of 2.1 % in a recent series'). Thus, wound in-
fection persists as an important problem after 
minimally-invasive approaches. 
 Several wound-edge protectors, such as Steri-Drape" 
(Minnesota Mining and Manufacturing Company, 3M, 
St. Paul, MN) or Vi-drape" (Parke-Davis, Morris 
Plains, NJ) have been shown to prevent wound con-
tamination and subsequent infection during conven-
tional abdominal surgeries","). However, Nystrom et al. 
reported that a different wound ring drape, Op-drap 
eTM (Triplus, Sweden), prevented neither contamination 
nor infection in a controlled, randomized study for 
elective colorectal surgery"). Thus, the efficacy of 
wound-edge drapes to prevent contamination and in-
fection in colorectal surgery remains controversial"). 
Wound infections typically result from bacterial con-
tamination with intestinal flora. Moreover, incidence of 
wound infections after extensive abdominal surgery 
appears related to factors other than simply operative 
contamination, such as reception of blood transfusions 
and patient immunocompetence17) . While the studies 
mentioned above involved conventional open colorec-
tal surgery, laparoscopic surgery has been shown to 
reduce the risk of infectious complications"). Further 
studies similar to these with minimally-invasive
approaches, such as laparoscopy or minilaparotomy, 
will be necessary to demonstrate an effect in this 
population. 
 In some earlier studies, the incidence of wound tumor 
recurrence following laparoscopic colorectal cancer sur-
gery far exceeded that reported for open surgery',","). 
However, recent reports of large series have shown ac-
ceptably low numbers of wound tumor recurrences; 
0% or less than 1%'0-"). Several hypotheses as to the 
mechanism of wound seeding have been posed. Nduka 
et a124). have identified three factors that may predis-
pose to an increased implantation rate: exfoliation of 
malignant cells following excessive manipulation by 
laparoscopic instruments, increased contact between 
the malignant cells and skin incisions, and the pres-
ence of a pneumoperitoneum. Preventing contamina-
tion of tumor cells during the laparoscopic-assisted 
procedure is an important issue in laparoscopic-
assisted surgery. Approximately 80% of abdominal 
wall recurrences following laparoscopic colon cancer 
surgery occur within one year'). In the current study, 
none of 22 patients in the Lap-Protector" group with 
follow-up beyond one year developed tumor recurrence 
at the minilaparotomy wound following minimally-
invasive approaches. However, because the follow-up 
period of all patients in this study was limited, long-
term follow-up for tumor recurrence in the minila-
parotomy wound will be necessary. 
 Wound ring drapes (Steri-Drape" etc) other than 
the Lap-Protector" are not ideal for laparoscopic-
assisted surgery, as these are designed as large drapes 
for use during laparotomy in conventional abdominal 
surgeries. In contrast, the Lap-Protector" is designed 
specifically for laparoscopic-assisted surgeries as a small 
device that does not interfere with the surgeon's per-
formance of the procedure. Furthermore, this new device 
(Lap-Protector" ) is particularly useful in gasless 
laparoscopic surgery with minilaparotomy25). Since 
gasless laparoscopic-assisted surgeries do not require 
sealing of the abdominal wall for pneumoperitoneum, 
the Lap-Protector" can be kept attached to the 
minilaparotomy site throughout the laparoscopic proce-
dure. 
 The advantages of the Lap-Protector T' are four-fold: 
1) simple utilization, 2) wound protection, as it does 
not cause damage to the minilaparotomy wound and 
reduces the chance that the minilaparotomy wound 
will come into contact with other tissues and organs, 
3) wound access, as it provides a round and relatively 
wide opening in the abdomen due to the tension of 
the silicon rubber, and 4) low cost. 
 In summary, the Lap-Protector T' device represents a 
safe and useful method to maintain patency of the
small incisions within the abdominal wall performed 
during minimally-invasive surgical procedures, im-
prove visibility, and prevent wound infections. Longer 
follow-up is necessary to evaluate its usefulness in pre-
venting wound site tumor recurrences.
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